Beone Medicines

Beone Medicines company information, Employees & Contact Information

Explore related pages

Related company profiles:

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-event/.

Company Details

Employees
1.97K
Founded
-
Address
55 Cambridge Pkwy, Cambridge,massachusetts 02142,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, Massachusetts
Looking for a particular Beone Medicines employee's phone or email?

Beone Medicines Questions

News

BeOne Medicines to Present at Upcoming Investor Conferences - The AI Journal

BeOne Medicines to Present at Upcoming Investor Conferences The AI Journal

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 - TradingView

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 TradingView

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA - Yahoo Finance

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA Yahoo Finance

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology - Business Wire

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology Business Wire

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million - Yahoo Finance

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million Yahoo Finance

BeOne's Breakthrough: New Clinical Data Shows 16% Response Rate in Advanced Breast Cancer Trials - Stock Titan

BeOne's Breakthrough: New Clinical Data Shows 16% Response Rate in Advanced Breast Cancer Trials Stock Titan

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 - The AI Journal

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 The AI Journal

BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting "1+" to Accelerate the Delivery of Innovative Cancer Therapies - Laotian Times

BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting "1+" to Accelerate the Delivery of Innovative Cancer Therapies Laotian Times

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 - PharmiWeb.com

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 PharmiWeb.com

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Business Wire

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference Business Wire

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® - FinancialContent

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® FinancialContent

200K+ Patients Treated: BeOne's BRUKINSA Cancer Drug Gets EU Approval for New Patient-Friendly Tablet Form - Stock Titan

200K+ Patients Treated: BeOne's BRUKINSA Cancer Drug Gets EU Approval for New Patient-Friendly Tablet Form Stock Titan

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene Business Wire

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 - Business Wire

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 Business Wire

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia - Yahoo Finance

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia Yahoo Finance

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference Business Wire

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor Business Wire

for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy - Business Wire

for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Business Wire

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region - Business Wire

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region Business Wire

Top Beone Medicines Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant